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Background. Hypertensive nephrosclerosis is the pre-
sumed underlying cause in many end-stage kidney
disease (ESKD) patients, but the diagnosis is
disputed and based on clinical criteria with low
diagnostic accuracy.
Objective. To evaluate and improve the diagnostic
process for nephrosclerosis patients.
Methods. We included adults from the population-
based HUNT study (n = 50 552), Norwegian CKD
patients referred for kidney biopsy 1988–2012
(n = 7261), and unselected nephrology clinic
patients (n = 193) used for matching. Decision tree
analysis and ROC curve-based methods of optimal
cut-offs were used to improve clinical nephroscle-
rosis criteria.
Results. Nephrosclerosis prevalence was 2.7% in the
general population, and eGFR decline and risk for
kidney-related hospital admissions and ESKD
were comparable to patients with diabetic kidney
disease. In the biopsy cohort, current clinical
criteria had very low sensitivity (0.13) but high
specificity (0.94) for biopsy-verified arteri-
onephrosclerosis. A new optimized diagnostic algo-
rithm based on proteinuria (<0.75 g d1), systolic
blood pressure (>155 mm Hg) and age (>75 years)
only marginally improved diagnostic accuracy
(sensitivity 0.19, specificity 0.96). Likewise, there
were still false-positive cases with treatable diag-
noses like glomerulonephritis, interstitial nephritis
and others (40% of all test positive). Decision curve
analysis showed that the new criteria can lead to
higher clinical utility, especially for patients con-
sidering the potential harms to be close to the
potential benefits, while the more risk-tolerant
ones (harm:benefit ratio < 1:4) should consider
kidney biopsy.
Conclusion. Further improvements of the current
clinical criteria seem difficult, so risks and benefits
of kidney biopsy could be more actively discussed
with selected patients to reduce misclassification
and direct treatment.
Keywords: chronic kidney disease, clinical criteria,
diagnostics, harm-to-benefit analysis, kidney
biopsy, nephrosclerosis.
Introduction
The incidence of patients with end-stage kidney
disease (ESKD) ascribed to hypertensive
nephrosclerosis has increased strongly in Europe
and the United States over the past 20 years and
now constitutes 15% and 28% of all new cases,
respectively [1,2]. However, only a few of these
patients have a biopsy-verified diagnosis, and the
accuracy of clinical criteria used to diagnose
nephrosclerosis has long been questioned [3–5].
These problems are also reflected by the wide range
of incidence estimates for end-stage nephrosclero-
sis reported across Europe (5%–33% of ESKD
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cases) [2]. In addition, the prevalence and progno-
sis of hypertensive nephrosclerosis in population-
based studies are not well established.
The clinical diagnosis of nephrosclerosis is one of
exclusion and typically consists of long-standing
hypertension, the absence of diabetes, haematuria,
overt proteinuria and the absence of other known
CKD causes. Studies on the diagnostic accuracy of
these clinical criteria are few, and prior studies
have often had suboptimal designs [6–11]. Positive
predictive value of 97% in African American
patients (n = 39), 75% in Chinese (n = 63), 65% in
Brazilian (n = 81) and 48% in Italian (n = 56)
patients has been reported [7,9–11]. However,
positive (and negative) predictive values are influ-
enced by the prevalence in the population being
evaluated. Sensitivity and specificity are better
measures of diagnostic accuracy, but this necessi-
tates biopsy verification of both test-positive and
test-negative cases. We recently demonstrated that
the current clinical nephrosclerosis criteria have
very low sensitivity (17%) but high specificity (94%)
in a large cohort of patients referred to kidney
biopsy [12]. However, these findings could be
influenced by the inevitable selection bias of kidney
biopsy registries. Others have suggested that
hypertensive nephrosclerosis patients should
demonstrate subclinical organ damage like left
ventricular hypertrophy, [6,8] but these stricter
criteria are used more seldom in clinical practice
and fewer scientific reports are available.
We therefore studied prevalence, phenotype and
prognosis in subjects with hypertensive
nephrosclerosis based on clinical criteria who are
living in the general population. We aimed to
optimize the current clinical diagnostic criteria
using patients with arterionephrosclerosis and
other relevant biopsy-verified diagnoses after
matching these patients to unselected nephrology
outpatient clinic patients. Diagnostic challenges in
hypertensive nephrosclerosis are closely linked to
kidney biopsy indications and the risk for compli-
cations, and we therefore included patient’s per-
ception of the trade-off between harm and benefit




We included subjects from the Norwegian popula-
tion-based Nord-Trøndelag Health Studies (HUNT)
as indicated in Fig. 1. Nord-Trøndelag county has a
population of 130 000 residents (>97% white) and
is representative of Norway in regard to demo-
graphics, income, mortality and morbidity, includ-
ing ESKD risk. Furthermore, relevant aspects of
Norwegian health care in general and kidney
medicine, in particular, are not substantially dif-
ferent from that in the rest of Europe and the
United States [13]. HUNT invites all residents of
Nord-Trøndelag County to participate every
10 years, and the participation rates have been
very high with more than 50% of all adults in the
county included in the examinations [14]. The
study comprises extensive data on medical history
and risk factors, a clinical examination, and dona-
tion of blood and urine. Information on total CKD
prevalence, trends, patient characteristics and
methods in the HUNT studies has been published
previously [13,15,16]. Hypertensive nephrosclero-
sis was defined as long-standing hypertension
(blood pressure ≥ 140/90 mm Hg or antihyperten-
sive treatment in both HUNT-2 (1995–1997) and
HUNT-3 (2006–2008)) with estimated glomerular
filtration rate (eGFR) <60 mL1 min1 1.73 m2, no
diabetes, no history of glomerulonephritis or other
kidney diseases, no haematuria and only mild to
moderate proteinuria (albumin creatinine ratio
(ACR) <30 mg mmol1 or <0.5 g protein day1) at
the HUNT-3 examination [17]. Hypertensive par-
ticipants were not evaluated for secondary causes,
and CKD cases were not referred for further
diagnostic evaluations. Diabetic kidney disease
(DKD) was defined as physician-verified diabetes
mellitus with severely increased urinary albumin
excretion (ACR ≥ 30 mg mmol1) or eGFR <
60 mL1 min1 1.73 m2. Subjects fulfilling the
CKD criteria put forward by KDIGO (eGFR <
60 mL1 min1 1.73 m2 or ACR > 3 mg mmol1)
but not classified as nephrosclerosis or DKD were
grouped as ‘other CKD’.
The Norwegian Kidney Biopsy Registry (NKBR)
collects clinical and histopathological data for all
Norwegian patients who undergo kidney biopsy.
The cohort consists of >90% whites, and the biopsy
frequency was 150 per million inhabitants per year
in 2013 [18]. The registry classifies the biopsy as
arterionephrosclerosis if typical findings occur in
the absence of other primary renal diagnoses. In
patients with other findings like diabetes, glomeru-
lonephritis and amyloid combined with arteri-
onephrosclerosis, the latter is registered as an
additional diagnosis only and not considered in the
current study. Further details on the
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histopathological diagnosis of arterionephrosclero-
sis are given in the Appendix S1 [19]. In addition,
representative clinical data obtained prior to the
biopsy are provided by the local nephrologist:
indication for kidney biopsy (nephrotic syndrome,
nephritic syndrome, proteinuria, haematuria, pro-
gressive decline in kidney function or acute decline
in kidney function), age, sex, height, weight, blood
pressure, antihypertensive medication use, and
selected blood and urine laboratory values.
We excluded patients from the kidney biopsy reg-
istry who either had a clinical presentation that
made arterionephrosclerosis very unlikely, or where
a specific diagnosis could be made with high prob-
ability based on clinical criteria or noninvasive
blood testing alone (Fig. 1): nephrotic syndrome,
ANCA-associated vasculitis, anti-glomerular base-
ment membrane glomerulonephritis, thrombotic
microangiopathy and light-chain cast nephropathy.
Included patients therefore comprise a relevant mix
of arterionephrosclerosis andother caseswhere this
diagnosis could not be accurately ruled out by
clinical presentation or noninvasive tests.
We also studied patients from three hospital-based
outpatient clinics considered representative for
Norway (one local hospital covering the same area
as the HUNT study and two large university hos-
pitals). We included patients where an experienced
nephrologist, without doing a kidney biopsy, had
concluded that hypertensive nephrosclerosis was
the most probable CKD diagnosis: clinical history,
physical examination, urine and blood findings,
and radiological examinations were integrated with
information from the patient’s general practitioner
and other sources over time as well as the nephrol-
ogist’s clinical experience. We registered important
clinical variables like age, sex, systolic and dias-
tolic blood pressure, diabetes status, BMI, eGFR,
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Fig. 1 Flow chart showing selection of study participants from the population-based HUNT studies and nephrology
outpatient clinics (including the Norwegian Kidney Biopsy Registry (NKBR), HN, hypertensive nephrosclerosis).
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urinary protein excretion, haematuria, total
cholesterol and HDL cholesterol. This information
was used for matching biopsy-verified arteri-
onephrosclerosis to reduce selection bias [20].
All patients were observed until December 2017 by
linkage to the Norwegian Cause of Death Registry
and the Norwegian Nephrology Registry, which are
both regarded as more than 99% complete regard-
ing death and ESKD status, respectively. For HUNT
participants, we also retrieved information on
hospital admissions as well as all serum creatinine
tests taken by their general practitioners or at
outpatient clinics after HUNT3 (2006–2008) to
provide information on individual eGFR slopes.
Statistics
We used STATA 13 for statistical analysis (Stata-
Corp LP, College Station, TX, USA). The proportion
of missing data for central variables used for
clinical diagnosis of arterionephrosclerosis was
low to medium in the Norwegian Kidney Biopsy
Registry and in HUNT (2%–16%). However, ACR
measurements in three urine samples were only
done in HUNT participants with diabetes, hyper-
tension or a 5% random subsample, that is these
data were missing by design for 85% of HUNT
participants. 26% of HUNT-3 participants did not
have blood pressure measurements from the
HUNT-2 examination. We used multiple imputa-
tion with chained equations creating 20 datasets of
each database, which were then combined accord-
ing to Rubin’s rules and used in standard statis-
tical analysis [13,16,21–27].
Baseline characteristics were described as mean
(standard deviation) and percentage. Prevalence
estimates in the HUNT cohort were adjusted for
nonattendance. Prognosis was described with
Kaplan–Meier plots, and we calculated age-ad-
justed rates of outcomes using standardized mar-
gins (STATA commands logistic with adjustment for
age, followed by margins). Relative risk associa-
tions with adjustment for multiple covariates were
assessed with Cox regression analysis. For ESKD,
we used competing-risks regression based on Fine
and Gray’s proportional subhazards model. Diag-
nostic accuracy was evaluated as sensitivity/speci-
ficity and positive/negative likelihood ratios since
these measures are less dependent of prevalence
and enable proper adjustment of pretest probabil-
ity in individual patients. However, these measures
are still influenced by spectrum bias, so we used
coarsened exact matching (CEM) to select subjects
and generate weights to match relevant kidney
biopsy patients to the more typical arteri-
onephrosclerosis patient diagnosed at the outpa-
tient clinics by a nephrologist without biopsy.
Variables were first compared using t-test or chi-
square test, and those with a false detection
rate < 0.05 using Benjamini Hochberg ranking
procedure were used for matching.
We used several analytical approaches to evaluate
and improve the clinical criteria for nephrosclero-
sis. Multiway decision tree analysis was performed
with the RapidMiner Studio 6.1 software (RapidMi-
ner Inc., Cambridge, MA, USA), which uses a C.4-5
like algorithm to study the type, order and cut-off
values of variables. Optimal cut-offs for important
variables were also assessed with ‘Optimal Cut-
points’ package using various evaluations of recei-
ver operating characteristics (ROC) analysis (ROC
01, Youden index, specificity > 0.90, equal sensi-
tivity and specificity, and likelihood ratios of 2.0
and 0.5 for positive and negative tests, respectively)
[28]. ROC 01 chooses the ROC curve point closest
to the upper left corner (i.e. minimizes (speci-
ficity  1)2 + (sensitivity  1)2). Youden index is
the ROC curve point with the largest difference
between the true-positive rate and the false-posi-
tive rate (i.e. maximizing sensitivity + speci-
ficity  1). We also built a logistic regression
model based on information from the previous
analysis for diagnosing arterionephrosclerosis.
Internal validation with 10-fold cross validation
was used to assess realistic performance measures
(RapidMiner X-validation process).
Finally, decision curve analysis (DCA) was used to
compare the clinical utility of different diagnostic
strategies: biopsy all relevant cases, biopsy none,
or biopsy if a ‘test’ for nephrosclerosis is negative
[29–32]. DCA describes the relationship between
disease prevalence, predictive characteristics of the
test (e.g. a referral algorithm) and individual
patient perceived harm-to-benefit ratio for the
intervention. Clinical utility (net benefit) = (true
positives/N)  (false positives/N) 9 (Pt/1Pt),
where Pt (probability threshold) is the level of
diagnostic certainty above which the patients
would choose to have the intervention. The (Pt/
1Pt) factor is equivalent to the harm:benefit ratio,
that is a factor to incorporate the patient’s percep-
tion of harms and benefits associated with kidney
biopsy and, potentially, disease-specific treatment.
No specific harm:benefit ratio is substantiated for
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individual patients, rather the DCA visualizes the
clinical utility of all referral algorithms over the full
range of harm:benefit ratios. See Appendix S1 for
further DCA details and statistical methods in
general.
All participants gave informed consent when
included in the NKBR and the HUNT study. The
current study was approved by the Regional Com-
mittee for Medical and Health Research Ethics, the
Norwegian Data Protection Authority and the Nor-
wegian Ministry of Health.
Results
We included subjects from the general population,
nephrology outpatient clinics, and a national kid-
ney biopsy registry (Fig. 1). The prevalence of
hypertensive nephrosclerosis, diabetic kidney dis-
ease, and other CKD diagnoses was 2.7%, 2.0%
and 6.3%, respectively, in the general Norwegian
population, 2006–2008, after adjusting for non-
participation. The 1270 included subjects with a
clinical nephrosclerosis diagnosis were, by defini-
tion, all hypertensive with a mean blood pressure
of 143/73 mm Hg, without diabetes mellitus, and
with no or only moderate albuminuria (A1–A2)
(Table 1). Compared to other CKD patients in the
general population, they had higher age and lower
eGFR.
The mean eGFR decline in subjects without CKD
was 0.71 mL1 min1 1.73 m2 per year (95% con-
fidence interval 0.70–0.72). The eGFR decline in
patients with nephrosclerosis, diabetic kidney dis-
ease, and other CKD diagnoses was 1.99 (1.95–
2.04), 1.54 (1.49–1.60), and 0.97 (0.94–1.00)
mL1 min1 1.73 m2 per year, respectively. Long-
term prognosis for patients with hypertensive
nephrosclerosis and other diagnoses in the general
population is displayed in Fig. 2. Nephrosclerosis
patients had the highest absolute mortality risk;
half of patients had died within 10 years (Fig. 2a).
On the contrary, ESKD was a very rare event in the
general population, and the ESKD-free survival
lines for hypertensive nephrosclerosis and DKD
were not different (Fig. 2b). However, the
nephrosclerosis patients were substantially older
than the other groups. Table 2 displays age-ad-
justed rates for death and ESKD as well as rates for
hospital admittance due to acute or chronic kidney
disease. In general, subjects without CKD had a
low absolute 10-year risk for these kidney-related
outcomes (<1%), while the age-adjusted risk in
nephrosclerosis patients was several times higher
and similar to DKD patients. Table 3 displays
relative risks after further adjustments for age,
sex, blood pressure, body mass index and smok-
ing. Total mortality risk was significantly lower in
patients with nephrosclerosis compared to DKD
patients but worse than the other CKD patient
group. The multi-adjusted relative risk for ESKD
was similar for nephrosclerosis and DKD. There-
fore, patients with clinically diagnosed hyperten-
sive nephrosclerosis experience substantially
increased risks for kidney-related outcomes.
However, diagnosing hypertensive nephrosclerosis
based on clinical criteria in a population-based
registry can be inaccurate, while on the other hand
biopsy-verified cases are selected and could poten-
tially lead to biased results. Cases diagnosed by
nephrologists at outpatient clinics with access to
extensive clinical, biochemical and imaging data
collected over time are a more representative
cohort. We therefore studied clinical characteris-
tics in 90 nonbiopsied patients with a diagnosis of
hypertensive nephrosclerosis based on a nephrol-
ogist, as well as 4920 patients with biopsy-verified
kidney diagnoses who presented with characteris-
tics consistent with nephrosclerosis (Table 1).
Many biopsy-verified arterionephrosclerosis
patients suffered from diabetes (9.5%), had a
positive dipstick for haematuria (34%) and
excreted substantial amounts of protein (mean
1.7 g d1) (Table 1). This was atypical compared
to current clinical criteria, but similar characteris-
tics were found in the nonselected outpatient clinic
cases. The biopsy-verified cases did have younger
age and lower BMI (FDR < 0.05 after adjusting for
multiple testing), so further analyses on the
biopsy-verified cases were therefore matched on
these variables.
The diagnostic accuracy of current clinical criteria
and other diagnostic algorithms were tested in the
biopsy cohort after matching to the nonbiopsied
outpatient nephrosclerosis group to reduce selec-
tion bias. When comparing the discriminative
potential of various components of the current
clinical nephrosclerosis criteria, low proteinuria
(<0.5 g d1) and hypertension had the highest
specificity (0.66 and 0.55, respectively) (Table 4).
The combination of these two variables had high
specificity (0.88) and adding absence of haema-
turia increased specificity even further (0.94).
However, the sensitivity was low for most individ-
ual criteria and for their combinations. Overall, the
Diagnostics in nephrosclerosis / S. I. Hallan et al.
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current criteria had a sensitivity of 0.13 and a
specificity of 0.94.
We therefore performed additional analyses to
explore the potential for improving the clinical
diagnostic criteria. Decision tree analysis was used
to evaluate the order, cut-off and type of variables
to include in a model. Lower proteinuria
(<0.75 g d1), higher systolic blood pressure
(>155 mmHg) and higher age (>75 years) were
suggested as major criteria (Fig. 3). Additional
evaluation with various receiver operation curve
(a)
(b)
Fig. 2 Total and ESKD-free survival by kidney diagnosis in the general population (figures a and b: 4827 deaths and 67
patients starting RRT over 494 892 observation years).
Diagnostics in nephrosclerosis / S. I. Hallan et al.
ª 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 7
Journal of Internal Medicine
(ROC)-based methods confirmed that these cut-
offs were optimal in most sensitivity/specificity
trade-off scenarios (Table 5). Based on these find-
ings, we suggested a new dichotomous model (‘New
Clinical Criteria’) for diagnosing nephrosclerosis
with slightly higher proteinuria cut-off
(<0.75 g d1) as the first criterion and adding age
(>75 years) to the subgroup with high systolic
blood pressure (>155 mm Hg) while those with
lower blood pressure should have very low protein-
uria (<0.10 g d1), see Fig. 3. We also suggested a
regression-based model (‘New Regression Model’)
using continuous (age, blood pressure and pro-
teinuria) as well as dichotomous (sex, haematuria
and diabetes) variables. The ‘New Clinical Criteria’
had improved sensitivity (0.19) and specificity
(0.96) compared to ‘Current Clinical Criteria’ with
the diagnostic odds ratio (DOR, i.e. the likelihood
ratio for a positive test divided by the likelihood
ratio for a negative test) increasing from 2.4 to 5.7
(Table 6). However, there was still many false-
positive cases with other treatable diagnoses like
glomerulonephritis, interstitial nephritis and other
diagnoses (40% of all with positive test). The ‘New
Regression Model’ had slightly higher sensitivity
(17% vs. 13%) for the equivalent level of specificity
(94%) compared to the current criteria, which
combined into a moderately improved DOR value
(3.3).
The clinical utility of these diagnostic algorithms
also depends on the individual patient’s valuation
of harms (biopsy risk, financial costs, concerns,
etc.) versus benefits (potential improved health
outcomes due to more specific confirmation of the
diagnosis and directed treatments). Fig. 4 shows
that if a patient and his or her provider judge that
the risks of biopsy equals the benefits (harm:
benefit ratio 1:1), the best overall strategy to
diagnose nephrosclerosis was to use the ‘New
Clinical Criteria’ model (red line), while all other
alternatives would do more harm than good (neg-
ative utility). The ‘New Clinical Criteria’ model also
remains the best option for patients considering
the harm:benefit ratio to be more favourable, i.e.
decreasing (e.g. harm:benefit ratios from 1:1 to
1:4). However, since algorithms based on clinical
variables have a low diagnostic accuracy, patients
considering the harm:benefit ratio to be <1:4
should choose the ‘Biopsy All’ option.
Discussion
The prevalence of hypertensive nephrosclerosis
was high in the general population, but the current
clinical criteria had low diagnostic accuracy. How-
ever, the diagnosis nevertheless carried a substan-
tially increased risk for ESKD and death.
Diagnostic strategies based on new optimized clin-
ical criteria had, after considering patients’ valua-
tion of risks and benefits, a small but significantly
higher clinical utility than current clinical criteria.
Risk-willing patients could consider the ‘Biopsy All’
option to avoid a false-positive diagnosis of
nephrosclerosis and thereby losing the opportunity
of more specific treatment of their kidney disease.
The true prevalence of nephrosclerosis in the
general population is unknown since there has
been a general advice against biopsying CKD
patients without proteinuria or haematuria. Italian
studies found that hypertensive/ischaemic
nephropathy posed one quarter of CKD, which
gave a prevalence of 3.4% at age over 40 years
[33,34]. A Japanese study used nonproteinuric
CKD as a proxy for hypertensive nephrosclerosis
Table 2. Ten-year age-adjusted rates for death and kidney-related outcomes in the general population (HUNT-3) by CKD
diagnoses
Outcome No CKD (n = 45 444) HN (n = 1270) DKD (n = 978) Other CKD (n = 2894)
Death risk (%, n = 4827) 23.3 (22.6–23.9) 30.9 (29.1–32.8) 37.0 (34.6–39.4) 27.7 (26.2–29.3)
ESKD risk (%, n = 67) 0.05 (0.03–0.08) 1.3 (0.6–1.9) 1.5 (0.8–2.3) 0.5 (0.2–0.7)
CKD hospital
admittance (%, n = 309)
0.5 (0.3–0.6) 5.7 (4.7–6.8) 4.8 (3.5–6.1) 2.4 (1.7–3.0)
AKI hospital
admittance (%, n = 271)
0.9 (0.7–1.0) 2.7 (2.0–3.4) 3.2 (2.1–4.3) 1.6 (1.1–2.1)
Marginal standardization (logistic regression followed by margins) was used to estimate 10-year rates (% with outcome
within 10 years) adjusted for age (95% confidence intervals).
DKD, diabetic kidney disease; HN, hypertensive nephrosclerosis.
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and estimated a prevalence of 10% in women and
15% in men above the age of 40, but these
diagnostic criteria were much wider than in most
other studies [35]. We found that the current
clinical criteria classified 2.8% of the general adult
population as hypertensive nephrosclerosis (3.8%
at age 40+), but the true prevalence could be
substantially higher given the high number of
false-negative cases versus the number of false-
positive cases.
The prognosis for patients diagnosed with hyper-
tensive nephrosclerosis in the general population
using clinical criteria is studied in few cohorts. A
very interesting Japanese study followed 50
patients with diabetic kidney disease and 50
patients with hypertensive nephrosclerosis diag-
nosed with biopsy or extensive clinical examina-
tions from CKD stage 2/3a to renal replacement
therapy initiation [36]. The overall kidney function
decline was not very different between DKD and
nephrosclerosis patients over this up to 20-year
observation period, but the DKD patients followed
a trajectory on the KDIGO heat map with an initial
phase with rather stable kidney function but
increasing albuminuria followed by a rapid decline
in kidney function. Hypertensive nephrosclerosis
patients, on the other hand, displayed a slower but
inexorable decline in kidney function from the
start of the study. Our population-based
nephrosclerosis patients were, except for a higher
age, quite similar to these Japanese cases and
displayed a rather similar mortality and ESKD risk.
Current data therefore indicate that even popula-
tion-based hypertensive nephrosclerosis patients
have a substantially increased risk and are not
merely normal ageing.
The diagnostic accuracy of the current clinical
criteria has only been studied in a few studies and
has been hampered with suboptimal designs. The
positive predictive value ranged 40%–97%, [7,9–12]
and the full diagnostic accuracy was not studied
until we recently gave estimates of both sensitivity
and specificity (0.17 and 0.94, respectively) [12]. To
improve this very disappointing accuracy, we need
more data on the performance of the individual
clinical criteria and suggestions of new diagnostic
algorithms, but we are not aware of any such
studies. Our current study indicates that hyper-
tension and proteinuria add specificity, while
absence of haematuria and high eGFR contribute
to sensitivity. However, the two latter criteria were
not selected by the decision tree analysis used to
build a more optimal diagnostic model. Instead,
age was selected, and >75 years was suggested as
cut-off in ROC-based analyses. Correspondingly,
we suggest higher cut-offs for proteinuria and
systolic blood than the current clinical criteria
(<0.75 g d1 and >155 mm Hg, respectively).
Selecting the optimal cut-off is a trade-off between
sensitivity and specificity. Traditionally, higher
sensitivity is prioritized when picking up more
true-positive cases is important, while higher
Table 3. Adjusted risk for death and ESKD in the general population by CKD diagnoses
Adjusted for age & sex
Adjusted for age, sex, sBP, BMI
and smoking
HR (95% CI) P-value HR (95% CI) P-value
Death
No CKD 1.00 (Ref.) 1.00 (Ref.)
Hypertensive nephrosclerosis 1.43 (1.31–1.57) <0.001 1.47 (1.33–1.62) <0.001
Diabetic kidney disease 1.93 (1.73–2.14) <0.001 1.91 (1.70–2.15) <0.001
Other CKD 1.32 (1.21–1.44) <0.001 1.27 (1.15–1.40) <0.001
ESKD
No CKD 1.00 (Ref.) 1.00 (Ref.)
Hypertensive nephrosclerosis 19.2 (6.1–60.0) <0.001 15.4 (4.6–51.9) <0.001
Diabetic kidney disease 17.7 (6.3–49.9) <0.001 18.8 (6.4–55.8) <0.001
Other CKD 7.8 (3.1–19.2) <0.001 6.8 (2.7–17.6) <0.001
Data are hazard ratios for experiencing death during the 10-year observation period (Cox regression) and sub hazard
ratios for experiencing ESKD before death (Fine Grey competing risk regression).
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specificity is suitable when we want to exclude a
diagnosis and avoid false-positive cases, for exam-
ple in a screening situation [37]. In the current
setting, these two goals are interwoven, and we
therefore focused on ROC 01 and the Youden
methods which prioritize total diagnostic
accuracy (total area under the ROC curve).
However, the optimized clinical criteria
Fig. 3 Decision tree analysis to
evaluate the order, cut-off and






Table 5. Optimal cut-offs with corresponding sensitivity and specificity for important nephrosclerosis variables based on
different selection methods
Method Proteinuria (g d1) Systolic BP (mm Hg) Age (years)







ROC 01 <0.8 (48/71) >155 (51/65) 150 (56/59) NA >75 (53/73)
Youden index <0.7 (47/72) >155 (51/65) 155 (47/71) NA >75 (53/75)
Specificity ≥ 0.85 <0.3 (17/92) >171 (23/86) 167 (20/86) NA >80 (9/88)
Equal Sens & Spec <1.3 (56/56) >150 (59/54) 145 (56/57) NA >72 (57/54)
LR = 2.0 for
positive test
<0.3 (16/92) >205 (3/99) 205 (3/98) NA >75 (53/73)
LR = 0.5 for
negative test
<3.2 (88/24) >100 (99/1) 111 (97/7) NA >58 (93/14)
For example, when using ROC 01 (selecting the point on the ROC curve closest to the upper left corner to maximize overall
accuracy), we find that the optimal cut-off for proteinuria is < 0.8 g d1 and the corresponding sensitivity is 48% and
specificity is 71%. Subgroups are chosen according to the results of the classification tree analysis: subgroup A is
proteinuria < 0.75 g d1; subgroup B is proteinuria < 0.75 g d1 and systolic blood pressure > 155 mm Hg.
NA, data not available since the overall ROC curve was not statistically different from a value of 0.500.
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(proteinuria < 0.75 g d1, systolic blood pres-
sure >
155 mm Hg, and age > 75 years) only led to a
moderate improvement of the diagnostic accuracy.
Further research is therefore strongly needed, and
noninvasive methods based on new –omics tech-
nologies could push the field forward [38].
Our study has some important limitations. The
optimal design should include all incident patients
with a clinical phenotype compatible with
nephrosclerosis and refer all patients to kidney
biopsy to get a definitive diagnosis. This is, how-
ever, neither ethical nor practical possible, and all
studies on the current topic will be influence by
selection bias. We tried to reduce such bias by
matching the biopsy-verified cases with nonbiop-
sied hypertensive nephrosclerosis cases from the
nephrology clinic for central characteristics, but it
is difficult to estimate the amount of residual bias.
Missing data were imputed to avoid bias, and we
used 10-fold cross validation to avoid overfitting of
new models. We included only white Northern
European subjects, and generalization to other
regions should be done with caution (and for
African Americans not at all). Although we did
internal validation to avoid overoptimistic perfor-
mance characteristics, external validation is
needed. Finally, we did not have information on
cardiovascular mortality, but it is reasonable to
assume that a large proportion of our CKD patients
died due to cardiovascular disease [39].
All things considered, our findings could have
important clinical consequences. Kidney biopsy
is, in general, a safe procedure when performed
lege artis, [40] but all recommendations highlight
the need to be sure that the risk of the procedure
and treatment is acceptable for the patient [41].
Decision curve analyses is a new technique to
include patient preferences and risk willingness,
[42] and the method has increasingly been used to
evaluate nephrology prediction models for mortal-
ity and ESKD risk, residual kidney function,
transplant outcomes and acute kidney injury risk
[43–46]. Studies have demonstrated that serious
(but nonlethal) biopsy complications occur in <5%,
while the biopsy information changes the diagnosis
in two thirds and the treatment in one third of
cases [47]. However, the harm:benefit (H:B) ratio
could be less advantageous in arterionephroscle-
rosis, and our ‘New Clinical Criteria’ model could
perform less favourable in other cohorts. Cur-
rently, there are no studies on how patients eval-
uate the specific harm versus benefit relationship
for diagnosing nephrosclerosis. In general, the
majority of patients tend to be risk averse. How-
ever, patients often accept higher risk than their
physician, and studies show that there is a sub-
stantial number of patients (15%–25% depending
on the clinical situation) who are willing to take
higher risks [48–51]. The risk willingness is only
weakly associated with patient characteristics, and
the biopsy complication risk and the clinical ben-
efit from a more precise diagnosis are not different
Table 6. Diagnostic performance of current and proposed diagnostic criteria for hypertensive nephrosclerosis
Current criteria New clinical criteria New regression model
Sensitivity (%) 13.2 (11.3–15.3) 19.2 (17.0–21.5) 16.9 (14.8–19.1)
Specificity (%) 93.9 (93.1–94.7) 96.0 (95.3–96.6) 94.1 (93.3–94.8)
Likelihood Ratio (+) 2.17 (1.79–2.63) 4.78 (3.93–5.82) 2.86 (2.39–3.42)
Likelihood Ratio () 0.92 (0.90–0.95) 0.84 (0.82–0.87) 0.88 (0.86–0.91)
Positive predictive value (%) 40.5 (35.9–45.2) 60.0 (55.2–64.6) 47.3 (42.8–51.8)
Negative predictive value (%) 77.6 (77.1–78.0) 79.1 (78.6–79.6) 78.3 (77.8–78.8)
Diagnostic Odds Ratio (LR+/LR) 2.36 5.69 3.25
95% confidence intervals for the estimates are given in parentheses. Data are from CKD patients with relevant biopsy-
verified diagnoses matched to clinical characteristics of typical arterionephrosclerosis patients diagnosed by a
nephrologist at the outpatient clinic without biopsy.
Current clinical criteria: hypertension (>140/90 mm Hg), proteinuria < 0.5 g/24 h, no haematuria, no DM and no other
CKD diagnosis.
New clinical criteria: proteinuria < 0.75 g/24 h, and age > 75 if systolic BP > 155 mm Hg or proteinuria < 0.10 g/24 h if
systolic BP < 155 mm Hg. New regression model: age, systolic BP, diastolic BP and proteinuria as continuous variables;
sex, haematuria and diabetes as dichotomous variables. (Probability cut-off for  HN was set to p(D) > 0.40 to achieve the
same specificity as the current clinical criteria to enhance the comparison between the diagnostic algorithms).
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in younger versus older patients. Although we
demonstrated that higher age increased the risk
of hypertensive nephrosclerosis, the clinical crite-
ria still had a low diagnostic accuracy. Kidney
biopsy is a relevant option even in elderly patients,
and physicians must therefore discuss or formally
evaluate each patient to elicit their evaluation of
these aspects.
In clinical practice, some patients and providers
will consider the H:B ratio for arterionephrosclero-
sis to be rather disadvantageous (>3:2). None of the
tested algorithms will give a positive clinical utility
for these patients, so the ‘Biopsy None’ option is the
best advice. Based on our clinical experience, we
estimate that many patients would consider the H:
B ratio to be in the 1:4 to 3:2 range. For these, the
‘New Clinical Criteria’ model is the best choice. For
low-risk patients wanting a more aggressive diag-
nostic approach (H:B ratio < 1:4), the ‘Biopsy All’
strategy could give higher benefit than the clinical
criteria-based options. However, whether and how
much the indications for biopsy should be widened
warrants further discussions and studies.
In conclusion, hypertensive nephrosclerosis is a
common disease and carries an increased risk of
kidney-related outcomes and death comparable to
DKD in the general population. Optimizing the
clinical criteria improved the clinical utility of the
current diagnostic process only moderately. A more
liberal biopsy policy could theoretically increase
benefit by reducing misclassification and direct
treatment for a subgroup of patients. Our study
highlights the need for further research on the
diagnostic process in patients suspected to have
hypertensive nephrosclerosis.
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